Octapharma: FDA Approves Blood Thinner Reversal Drug, But Requires More Tests to Assess Serious Risk

While Octapharma drug Balfaxar met the goal of its pivotal clinical trial, more deaths and blood clot problems were reported in the study drug arm versus the comparator group. The FDA is requiring a post-marketing study to further assess the drug's risks.